Labile Copper Test Enhances Evaluation for Wilson's Disease: Joshua Bornhorst, Ph.D.
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' labile copper assay (Mayo ID: LBCS) improves upon standard blood tests for Wilson's disease. The new test measures not just overall copper but also the fraction of copper that is bioavailable, or labile bound.
(00:32)
Can you tell us a little bit about yourself and your background?
(01:33)
Could you give us a brief overview of this assay?
(02:47)
Which patients should have this testing, and when should it be performed?
(03:48)
How would the results be used in patient care?